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Abstract 11 
This proof of concept study demonstrates the application of transmission Raman 12 
spectroscopy (TRS) to the non-invasive and non-destructive quantification of low levels 13 
(0.62 – 1.32 %w/w) of an active pharmaceutical ingredient’s polymorphic forms in a 14 
pharmaceutical formulation. Partial least squares calibration models were validated with 15 
independent validation samples resulting in prediction RMSEP values of 0.03 – 0.05 % w/w 16 
and a limit of detection of 0.1 – 0.2 % w/w. The study further demonstrates the ability of 17 
TRS to quantify all tablet constituents in one single measurement. By analysis of degraded 18 
stability samples, sole transformation between polymorphic forms was observed while 19 
excipient levels remained constant. Additionally, a beam enhancer device was used to 20 
enhance laser coupling to the sample, which allowed comparable prediction performance at 21 
60 times faster rates (0.2 s) than in standard mode. 22 
 23 
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1. Introduction 24 
Rapid, non-invasive and non-destructive quantification of tablet or capsule constituents 25 
requiring no sample preparation is an important analytical area in pharmaceutical 26 
manufacturing. This requirement is driven by the limitations of existing technologies, often 27 
chromatographic based methods such as high performance liquid chromatography (HPLC), 28 
which, by their nature, are destructive techniques, require consumables, and takes 29 
significant time in use and maintenance.  30 
An area of particular interest and high relevance to pharmaceutical applications is 31 
the quantification or identification of specific polymorphic forms of an active 32 
pharmaceutical ingredient (API) in a final dosage form. The necessity to quantify 33 
polymorphic forms often falls into two main areas. Firstly, from a commercial standpoint 34 
e.g. patent infringement, a patent may protect only one particular drug form. Secondly, 35 
efficacy assurance since the solubility (a function of polymorphic form) of the specific drug 36 
form will affect the bioavailability of the API. 37 
The current technologies available for polymorph quantification are necessarily 38 
solid state as chromatographic techniques dissolve the sample and consequently destroy the 39 
crystallinity. Techniques such as X-ray diffraction (XRD), solid-state nuclear magnetic 40 
resonance (ssNMR), near-infrared and Raman spectroscopies have been widely studied and 41 
reviewed.[1–4] 42 
 A promising tool recently introduced into this area is transmission Raman 43 
spectroscopy.[5,6] The technique has seen numerous applications in pharmaceutical 44 
analysis, primarily focused around quantification of API in solid dose forms [7–10] recently 45 
gaining regulatory approval for batch release testing. [11]   46 
The known advantages of Raman spectroscopy include high chemical specificity; 47 
the ability to quantify multiple constituents of a solid dose form,[12] the ability to analyse 48 
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polymorphs and crystalline state[13]; the high speed of analysis (<1 second)[14]; the 49 
absence of sample preparation; the absence of solvents and/or consumables and the non-50 
destructive nature of analysis compared with the traditional analytical techniques. TRS also 51 
exhibits these favourable characteristics with the additional benefit, compared to a 52 
traditional backscatter geometry, of robustness against subsampling due to its high bulk 53 
sampling capability of the transmission method.[15,16] TRS has also displayed reduced 54 
sensitivity to matrix effects such as particle size, compaction force and sample thickness 55 
compared to other spectroscopic methods (particularly NIR spectroscopy).[17] As such 56 
TRS promises to offer a compelling and effective test method for pharmaceutical 57 
manufacturing, especially in challenging area of low drug loadings (typically down to ~0.1 58 
– 1 % w/w). The technique’s limitations of note include: the inability to analyse 59 
uncomplexed ionic compounds (e.g. NaCl) and interference from fluorescence in cases 60 
where this overwhelms the Raman Signal. 61 
  The technique has been previously demonstrated in the area of quantification of 62 
polymorphic components in binary form, in simple mixtures ranging from 0 – 100%[13,18] 63 
and in pharmaceutical formulations containing 10%w/w drug load with Limit of Detection 64 
(LOD) of 0.6%w/w. [19]  65 
In this study we show, for the first time, comprehensive quantification of low level 66 
polymorphic forms (0.62 – 1.32 % w/w), an area where alternative techniques are often 67 
inapplicable due to limited sensitivity. Additionally we show the benefits of a beam 68 
enhancing technology enabling speeds of up to 60 times faster (0.2 seconds total acquisition 69 
time)  but with similar quantification performance. 70 
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2. Experimental 71 
2.1. Materials 72 
In this study, flufenamic acid (FA) polymorphic forms were used, as previously studied and 73 
considered to be bench stable. Flufenamic acid {Sigma-Aldrich, UK} forms I (FA I) and III 74 
(FA III) were prepared as previously described.[13] Excipients included Ac-Di-SoL® 75 
(croscarmellose sodium {FMC Biopolymer, UK}) and lactose monohydrate {Sigma-76 
Aldrich, UK}. Forms I and III were independently dispensed as a 17% premix in lactose 77 
monohydrate to assist with the weighing of very small quantities.  78 
These compounds were selected for their wide use within the pharmaceutical industries. 79 
Additional consideration was given to their characteristic Raman features, for example 80 
lactose is a good Raman scatterer whereas Ac-Di-Sol® lacks Raman features and is very 81 
fluorescent. 82 
2.2. Formulation 83 
Samples were prepared following a 12 point DoE design, Figure 1. The final %w/w for 84 
each constituent in each of the samples is shown in Table I. 85 
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 86 
Figure 1: DoE central composite-type design schematically shown.  87 
The centre point for each component is displayed in sample no. 7. Tablets were prepared by 88 
dispensing the weighed powder, total approx. 1.2g, into a pestle and mortar and grinding by 89 
hand. The mixed powder was then pressed into tablets weighing approx. 110 mg (103 – 115 90 
mg range) and measuring  approx. 2 mm (2.09 – 2.18 mm range) thick. From each sample 91 
10 tablets were made. 8 were used for calibration and 2 were kept aside for stability testing. 92 
Centre point validation samples, triplicate dispensing of sample no.7, were made up 93 
independently with a new independent premix of FA polymorphs. Again, a total of 10 94 
tablets were pressed per sample, 8 were used for calibration and 2 were kept aside for 95 
stability testing. A summary of samples and tablets (150 total) scanned are shown in  96 
Table II. 97 
Stability samples were heated at 90 °C for 5 hours, in order to induce polymorphic 98 
transformation as has been previously demonstrated. [20] 99 
Page 6 of 26 
 
Table I: formulation and content of each of the calibration and validation samples. Values displayed in % w/w 100 
composition 101 
Sample Form I Form III Ac-Di-Sol® Lactose Total API 
1 0.62 0.93 20.01 78.44 1.55 
2 0.77 1.25 15.76 82.22 2.02 
3 0.78 1.23 24.09 73.90 2.01 
4 0.81 0.82 24.23 74.13 1.64 
5 0.77 0.80 15.82 82.61 1.57 
6 0.98 1.32 19.79 77.91 2.30 
7 0.98 1.05 20.03 77.94 2.03 
8 0.96 0.71 20.05 78.27 1.68 
9 1.17 1.25 15.35 82.23 2.42 
10 1.19 1.23 24.24 73.34 2.42 
11 1.20 0.82 15.62 82.35 2.02 
12 1.20 0.83 24.09 73.88 2.03 
VAL 1 0.98 1.00 19.85 78.17 1.98 
VAL 2 0.98 0.98 20.06 77.98 1.96 
VAL 3 0.98 0.99 19.95 78.07 1.97 
 102 
Table II: Summary of tablets prepared 103 
Samples 
No. of sample 
points 
n 
DOE 
Sample no.’s 
 
Repeats per 
sample no. 
r 
No of tablets 
per sample 
t 
Total No. of 
tablets  
n x r x t 
Calibration 12 1 to 12 1 8 96 
Validation 1 7 3 8 24 
Stability 
12 
1 
1 to 12 
7 
1 
3 
2 30 
 104 
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2.3. Beam enhancer  105 
A Beam enhancer (‘photon diode’) element has been described previously.[14,21] The 106 
element comprised a of 25 mm diameter Iridian (Ottawa, Canada) bandpass filter centred at 107 
830 nm with a bandwidth of 2.2 nm (FWHM) and transmittance of  >90% at the central 108 
wavelength. 109 
The photon diode is in essence a ‘unidirectional’ mirror permitting the transfer of photons 110 
from one side and acting as a reflector for photons impacting on it from the other side. It is 111 
located in close proximity to the sample placed and is directly over the laser illumination 112 
zone to prevent the loss of diffusely scattered photons from the sample’s surface. As this 113 
loss can be substantial (>90 % of photons can escape by this mechanism) its prevention 114 
leads to much higher coupling efficiency of laser photons into the sample and much higher 115 
transmission Raman intensities. [21] 116 
2.4. Measurements 117 
The tableted samples were analysed using a TRS100 (Cobalt Light Systems Ltd., 118 
Oxfordshire, UK) transmission Raman instrument. The device utilises an automated sample 119 
tray. The CCD detector (iDUS, Andor, UK) and spectrograph (Headwall, USA) 120 
combination collects spectra over the wavelength range of 50- 2500 cm-1. Acquisition 121 
parameters included a 4 mm diameter laser illumination spot size, medium lens collection 122 
optics (collection area diameter of ~6 mm), 650 mW laser power (830 nm), 0.6 s exposure 123 
time × 20 accumulations (i.e. 12 s total acquisition time per sample) without the beam 124 
enhancer. Utilising the beam enhancing optics within the sample tray required a reduced 125 
laser power of 350 mW to avoid saturation and permitted using shorter acquisition times, 126 
0.01 s × 20 (0.2 s in total per sample).  127 
Spectral analysis and model building was performed using Solo software (Eigenvector, 128 
WA). 129 
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3. Results and Discussion 130 
Raman spectra of the pure API FA I and FA III indicated distinctive regions where the two 131 
polymorphs displayed different vibrational modes in Figure 2; e.g. the five most intense 132 
peaks of FA I are at 249, 786, 1001, 1334, 1609 cm-1, whereas FA III can be identified by 133 
peaks at 748, 998, 1050, 1295 and 1618 cm-1.  134 
Calibration spectra were scanned and analysed using partial least squares (PLS) quantitative 135 
modelling. Visualisation of the baselined and normalised spectra, Figure 3, this indicates 136 
subtle spectral variation, highlighting the importance of chemometric techniques when 137 
analysing very low doses.  138 
Calibration models for both standard acquisition parameter and with the beam enhancer for each tablet constituent are 139 
each tablet constituent are shown in 140 
 141 
Page 9 of 26 
 
Figure 4 and  142 
Figure 5. Model performance values are shown in Table III.  Firstly notable is the similarity 143 
of performance between Standard Acquisition values and Beam Enhancer values, with < 144 
0.004 difference in the R2 fit values and between 0.001 and 0.04 difference in root mean 145 
square error of calibration/cross validation (RMSEC/CV). Linear fit values of R2 ≈ 1.00 146 
indicate that all constituents could be modelled well. Lactose, Ac-Di-Sol and FA III models 147 
perform similarly with R2 values of ~ 0.98 compared to slightly lower values of ~0.89 for 148 
FA I. Model performance of the FA calibration models are reflected in the RMSEC/CV 149 
with a lower value being preferable. FA I calibration performs with slightly a higher value 150 
of ~0.06 compared to better performing FA III with a value of ~0.03. Both display similar 151 
values between RMSEC and CV indicating robustness of each calibration.  152 
Model parameters were optimised to include 4 latent variables, pre-processing steps 153 
comprised of baseline removal (Automatic Whittaker Filter), normalisation (Standard 154 
normal variate scaling) and mean centring over the spectral range 200-1800 cm-1. The latent 155 
variables for the standard acquisition and beam enhancer calibration model, along with the 156 
spectral difference of the FA I and FA III are shown in Figure 6. Latent variables for both 157 
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calibration models are comparable. The latent variables can be assigned as follows LV1and 158 
LV2; contain features of FA I and FA III and lactose. LV3; is characteristic of peak 159 
broadening and accounts differences between two polymorphic FA I and FA III forms. 160 
LV4; displays a characteristic shape (spectral split of half up half down centred around 161 
~900 cm-1) which is observed due to changes in thickness, which is more common in hand 162 
made tablets.   163 
Throughout model building various standard model parameters were tried and tested. These 164 
settings used here were considered to be marginally better than others as they use a wide 165 
spectral range, include all samples, and simple spectral pre-processing which follows good 166 
working practices for PLS model building with Raman spectra.  167 
Table III: Calibration Model Performance [   ] Standard Acquisition [   ] Beam Enhancer 168 
 
Form I Form III 
Ac-Di-
SoL® 
Lactose Total API 
R2 
0.891 0.976 0.984 0.985 0.940 
0.895 0.979 0.984 0.982 0.943 
RMSEC 
0.062 0.032 0.408 0.398 0.070 
0.061 0.031 0.440 0.427 0.068 
RMSECV 
0.064 0.033 0.436 0.426 0.072 
0.063 0.032 0.478 0.463 0.071 
 169 
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Validation centre points tablets were then scanned using the same acquisition parameters as the calibration, without and 170 
with the beam enhancer, and analysed (see 171 
 172 
Figure 7and  173 
Figure 8). 174 
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Prediction statistics and root mean square error of prediction (RMSEP), are shown in Table 175 
IV. These uncertainty values of 0.05 translate to and uncertainty of +/- 0.05% w/w on any 176 
prediction, which on a 1% nominal concentration results in a prediction window of 0.95 – 177 
1.05 % w/w.  178 
Stability samples were then scanned using the same acquisition parameters as the 179 
calibration and analysed and predicted using the PLS calibration models previously 180 
generated. Predictions are shown in 181 
 182 
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Figure 9 and  183 
Figure 10. The results, prediction statistics, are summarised in  184 
Table V. 185 
The stability samples PLS predictions indicate an increase in the prediction of FA I and a 186 
decrease in FA III from the original dispensed/calibration value. The total API predictions 187 
remain consistent.  This change in the samples was caused by heating of the tablet samples 188 
at 90 °C for 5 hours. The observed predictions fits with the previous knowledge that on 189 
heating FA III, if seeded, readily converts to FA I. [20] 190 
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From the sub plots displaying the PLS predictions of the stability samples, shown in 191 
 192 
Figure 9 and  193 
Figure 10,  we observe consistency in predictions of the excipients before and after heating. 194 
This observation suggests that these stability conditions only affect conversion of FA III to 195 
FA I while the excipient content remains consistent.   196 
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Overall we see an increase in RMSEP values for the stability samples (Table IV) compared 197 
to the centre point validation values (Table IV). This suggests that the heating has had an 198 
effect on prediction performance. This could be due to the fact that the predictions are no 199 
longer in the original calibration space (0.62 – 1.32 %w/w) for each of the polymorphic 200 
forms, as marked by the dashed lines.  201 
Interestingly within the stability sample predictions we observe a slight increase in the 202 
RMSEP values in the prediction of the excipients with the use of the Beam Enhancer. 203 
Previous work [22] has shown than the Beam Enhancer preferentially enhances the lower 204 
surfaces of a sample. This suggests that on heating the surface of the tablet may appear 205 
different than the bulk, hence we observe this slight difference in the excipient values.    206 
Additionally by measuring the total API content (see the last sub plot in 207 
 208 
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Figure 9 and  209 
Figure 10) we can observe that this quantification is consistent, albeit with slight divergence 210 
towards the lower total API content. Again this divergence could be attributed to the fact 211 
that the predictions are no longer in the original calibration space (0.62 – 1.32 %w/w) for 212 
each of the polymorphic forms, as marked by the dashed lines.  213 
 214 
Table IV: Centre point Validation Model Performance [   ] Standard Acquisition [   ] Beam Enhancer 215 
 
Form I Form III 
Ac-Di-
SoL® 
Lactose Total API 
RMSEP 
0.041 0.048 0.504 0.535 0.081 
0.037 0.049 0.476 0.527 0.076 
 216 
 217 
Table V: Stability Samples Model Performance [   ] Standard Acquisition [   ] Beam Enhancer 218 
 
Form I Form III 
Ac-Di-
SoL® 
Lactose Total API 
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 219 
 220 
 221 
 222 
 223 
 224 
Limit of detection values, shown in  225 
Table VI, were estimated from the quantitative models following ICH guidelines on 226 
validation of analytical procedures where the detection limit may be expressed as:[23] 227 
𝐿𝑂𝐷 =
3.3𝜎
𝑆
 228 
σ = standard deviation of the residual error of a regression 229 
S = slope of the calibration curve. 230 
 231 
Table VI: Limit of Detection values [   ] Standard Acquisition [   ] Beam Enhancer 232 
 
Form I Form III 
Ac-Di-
SoL® 
Lactose Total API 
LOD 
0.23 0.11 1.45 1.43 0.25 
0.22 0.11 1.60 1.55 0.24 
   233 
 234 
4. Conclusion 235 
It has been demonstrated that transmission Raman spectroscopy has the ability to quantify 236 
low levels (0.62 – 1.32 %w/w) of polymorphic forms of an API in intact tablets. The 237 
quantitative model has been validated with independent centre point samples, displaying 238 
RMSEP 
0.903 0.829 0.761 0.836 0.122 
0.857 0.794 1.315 1.383 0.109 
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satisfactory prediction and model statistics, with a RMSEP between +/- 0.04 to 0.05 % w/w 239 
uncertainty on predicted values.  The limit of detection was determined to be 0.1 – 0.2 % 240 
w/w. Additionally, we have demonstrated the ability to simultaneously quantify both API 241 
and the excipients within the formulation. The ability to quantify excipients with little 242 
additional effort demonstrates the selectivity possible with transmission Raman and has 243 
practical benefits in terms of process understanding and control. This has been achieved 244 
through the application of an efficient central composite DoE, Figure 1. 245 
Stability investigations displayed the expected transformation of the API FA III to FA I. 246 
Analysis of total API content indicated no significant degradation or loss of the API, 247 
indicating direct conversion. Quantification of excipients within the stability samples 248 
remained reasonable, indicating that the stability testing purely affected the API.  249 
 250 
Finally the use of beam enhancer technology was investigated in order to reduce the data 251 
acquisition time by a factor of 60. It has been demonstrated that there is no significant 252 
detriment in either calibration model performance or prediction of unknown samples (centre 253 
point or stability) when the beam enhancer technology is used in this application. 254 
 255 
Overall this work shows that transmission Raman spectroscopy as a suitable tool for 256 
analysis of low level polymorphic content in final pharmaceutical forms in a rapid manner. 257 
These features would make transmission Raman spectroscopy a suitable technology for at-258 
line and/or real-time release and testing.   259 
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6. Figures 328 
 329 
Figure 2: Raw individual component TRS spectra 330 
 331 
Figure 3: Calibration Spectra baseline subtracted and normalised coloured according to flufenamic acid type. 332 
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 333 
Figure 4: Standard Acquisition Calibration 334 
 335 
Figure 5:  Beam Enhancer Calibration 336 
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 337 
Figure 6:  Latent Variables for Standard Acquisition Models 338 
 339 
Figure 7: Standard Acquisition Validation 340 
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 341 
Figure 8: Beam Enhancer Validation 342 
 343 
Figure 9: Standard Acquisition Stability Samples 344 
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 345 
Figure 10: Beam Enhancer Stability Samples 346 
